<DOC>
	<DOC>NCT01191450</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of Chlorthalidone 25 mg + amiloride hydrochloride 5 mg association in the treatment of elderly patients with arterial hypertension.</brief_summary>
	<brief_title>Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension</brief_title>
	<detailed_description>To assess the efficacy and safety of the association of Chlorthalidone 25 mg + amiloride hydrochloride 5 mg (Diupress® Eurofarma) in the treatment of elderly patients with arterial hypertension, compared to Chlorthalidone 25mg (Higroton® Laboratório Novartis) in same presentation form. Some eligibility criteria: perform blood and urine tests; ECG (electrocardiogram); ABPM (Ambulatory Blood Pressure Monitoring; Echocardiogram;Doppler Echocardiogram</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<mesh_term>Amiloride</mesh_term>
	<criteria>Systolic blood pressure between 140 mmHg 159 mmHg Diastolic blood pressure between 90 mmHg 99 mmHg Subject aged ≥ 60 years old Be able to comply with instructions, attend study followup visits and be willing to participate in the research project. Diagnosis of stage 1 arterial hypertension with no prior treatment more than 120 days or uncontrolled during antihypertensive agent administration. Any serious or severe clinically significant medical condition. Psychiatric or neurological diseases A condition that, as per Principal Investigator's opinion, may interfere with the optimal participation in the study, or that may result in special risk to the patient. Participation in any other investigational study within 12 months prior to Visit 1. Known medical history of allergy, hypersensitivity or intolerance to any of the formulation compounds to be used in this study Routine prior use of diuretics Oral anticoagulant use Fast glycemia &gt; 150 mg/dL Medical treatment, not related to study, scheduled for the clinical trial duration; except nonserious, controlled comorbidities in current medical followup. Expected onset of additional antihypertensive drug after the study onset Acute myocardial infarction within last 6 months Prior decompensated coronary artery disease Known thyroid, renal or liver dysfunction, at investigator's discretion Obesity body mass index (BMI) &gt; 33 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>chlortalidone</keyword>
	<keyword>amiloride</keyword>
	<keyword>arterial hypertension</keyword>
</DOC>